Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

NCT00310388 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
376
Enrollment
INDUSTRY
Sponsor class

Stopped No longer any benefit in collecting data since retigabine has been withdrawn from market.

Conditions

Interventions

Sponsor

GlaxoSmithKline